PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 82 filers reported holding PMV PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,420,000 | -3.8% | 3,000,000 | -2.0% | 0.29% | +10.4% |
| Q2 2023 | $19,155,600 | +31.2% | 3,060,000 | 0.0% | 0.26% | +20.4% |
| Q1 2023 | $14,596,200 | -45.2% | 3,060,000 | 0.0% | 0.22% | -45.7% |
| Q4 2022 | $26,622,000 | -26.9% | 3,060,000 | 0.0% | 0.40% | -40.9% |
| Q3 2022 | $36,414,000 | -17.6% | 3,060,000 | -1.3% | 0.67% | -22.9% |
| Q2 2022 | $44,175,000 | -3.6% | 3,100,000 | +40.9% | 0.87% | +4.4% |
| Q1 2022 | $45,804,000 | +35.3% | 2,200,000 | +50.2% | 0.84% | +45.1% |
| Q4 2021 | $33,842,000 | -61.2% | 1,465,000 | -49.9% | 0.58% | -57.9% |
| Q3 2021 | $87,165,000 | +39.8% | 2,925,000 | +60.3% | 1.37% | +26.3% |
| Q2 2021 | $62,342,000 | -19.7% | 1,825,000 | -22.7% | 1.08% | -19.2% |
| Q1 2021 | $77,629,000 | -40.5% | 2,360,267 | +0.4% | 1.34% | -40.3% |
| Q4 2020 | $130,536,000 | +126.7% | 2,350,267 | +27.0% | 2.25% | +174.8% |
| Q3 2020 | $57,578,000 | – | 1,850,000 | – | 0.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |